Compare IMVT & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | TECH |
|---|---|---|
| Founded | 2018 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.1B |
| IPO Year | 2019 | 1995 |
| Metric | IMVT | TECH |
|---|---|---|
| Price | $38.87 | $70.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $33.00 | ★ $71.82 |
| AVG Volume (30 Days) | 1.5M | ★ 7.4M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | N/A | ★ $1,219,635,000.00 |
| Revenue This Year | N/A | $2.49 |
| Revenue Next Year | N/A | $6.40 |
| P/E Ratio | ★ N/A | $87.44 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $14.32 | $43.20 |
| 52 Week High | $39.28 | $72.16 |
| Indicator | IMVT | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 70.64 | 77.05 |
| Support Level | $25.13 | $57.46 |
| Resistance Level | N/A | $71.10 |
| Average True Range (ATR) | 1.32 | 1.48 |
| MACD | 0.12 | 1.24 |
| Stochastic Oscillator | 94.94 | 97.69 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.